Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Cancer Immunol Res. 2017 Apr 10;5(5):357–362. doi: 10.1158/2326-6066.CIR-16-0287

Figure 2.

Figure 2

(A) Progression-free survival, (B) Post-progression survival (PPS) in the acquired resistance cohort, (C) PPS in single-organ versus systemic progression, and (D) PPS cut-off at 15 months.